![]() |
|
![]() |
| Closest competitor does a lot of heavy lifting in this situation. Ancestry is the overwhelming leader in the find long lost relative space/your "roots" space. Look at https://www.ancestry.com/ and https://www.23andme.com/
23andme has basically given up on this part of the business.
Their pitch is health. But that pitch is murky with no good hook to keep you hooked for a monthly subscription. So after they get the initial $99 from the customer, most of the value customer is going to get is already served up in the first report. Maybe their big database will turn into making cancer drugs but maybe it wont. |
![]() |
| That’s a very glib HN take.
Interest in family trees predates Ancestry.com and will certainly outlast it. It’s not necessarily about contact. I’m not sure what’s controversial here. |
![]() |
| Im trying, really trying to understand what BIGFAM is about. Is it related to gut biome, and what the bacteria eats, and trying to find the genes for that? Or am I completely lost. |
![]() |
| The family tree is a big deal for Mormons due to their religious beliefs. They can baptise their ancestors, providing lost souls with a chance to convert after death. |
![]() |
| I got a photo of my great-great grandfather as a result of a DNA match as well as lots of other information about him - so I suppose it depends if that sort thing interests you or not. |
![]() |
| If you are sleeping with a prostitute isn’t there like an implied contract that you aren’t responsible for any resulting child? That is practically the entire purpose of prostitution. |
![]() |
| Zodiac signs is a good way of putting it.
I think as a country of immigrants—or colonizers—we all feel desperate for some sense of personal history and identity. |
![]() |
| It's sad that we have come to a point where people frown upon a company that makes a product and sells it, without luring their customers in with monthly subscriptions. |
![]() |
| Ancestry does more than genetic analysis. Their claim to fame is their tools to search through old public records to help one build their genealogy/family tree. |
![]() |
| Based on my parent poster's question we're already operating from the assumption that happening and I'm just explaining why that's bad, not how likely it is. |
![]() |
| https://investors.23andme.com/news-releases/news-release-det...
This is complicated. The don't just zip up all the customer data and send it over, at least they say that they run aggregated queries for GSK and just tell them the answer. But then they say that the data is "anonymized" before this, which seems unnecessary and impossible. Imho it's very difficult to anonymize any data, and especially something like DNA. Without an external audit amd some mathematical guarantee (e.g. differntial privacy) I work on the assumption that they do the bare minimum to pass legal muster but anyone who made the effort could confidently associate the data with real people after the fact. |
![]() |
| Anne's plan from the very beginning was to capitalize on the value of the human genome in drug development and medical testing. Frankly everything you need to know about the idea behind the company before its various pitfalls and pivots is here (2007): https://web.archive.org/web/20140312001152/http://www.wired....
(sorry, it takes a while to load but wired has killed most of their long-term links) IMHO she and Avey were just naive about the actual science and business of using genomic information for drug discovery. Remember, around the time the company started, the human genome had only recently been sequenced and Craig Venter was trying to capitalize on that, and lots of folks figured it would quickly turn into a multi-billion dollar market. On the other hand, the product is quite good at finding relatives (identity by descent) and to be honest I wish they'd run 23&me as just that service, without the medical angle. My father did 23&Me mainly to figure out more about his ancestry, but also it helped a number of children conceived via IVF (he had provided a sample for fertility testing many years before) identify and contact him (I can't even imagine what the experience was like; to me, it's just a bunch of half-siblings I didn't know about) |
![]() |
| That's a good question- I think he signed a consent form that would have allowed additional research on his donations. TBH my dad was suprised but pleased by the outcome. |
![]() |
| I'm glad your dad was happy about it, but it does kind of speak to the potential dangers of giving out your DNA (which is concerns many have around 23andMe). |
![]() |
| > wouldn’t compare any stock to DJT. MAGA voters value signaling, institutional investors playing games, foreign governments laundering money to the campaign, primary shareholder prepping for exit
You’re right for the wrong reasons. (EDIT: I'm wrong for no reason.) Dow Jones is obsolete [1]. Its value is in its brand, i.e. other people look at it. The other factors you mention are noise. Relevant to a trader or market maker with infintessimal time horizons. But irrelevant to an investor thinking even in months. The American markets are simply too deep. The totality of dollars at work by MAGA voters, game-playing hedge funds and money launderers--through the stock market--is negligible. (Lots of political tea-leave reading funds have been attempted. Zero prevail.) [1] https://retirementresearcher.com/why-the-dow-doesnt-work/ |
![]() |
| Anne Wojcicki is also the exwife of billionaire Google founder Sergey Brin.
I have always felt as if 23andMe was just her pet lil project and it doesn't matter if its ever profitable or not. |
![]() |
| So sad that Blackstone bought ancestry.. newspapers.com is a really nice tool for researchers (and most things that get touched by PE end up enshittified) |
![]() |
| Can you show damages? If you can win a lawsuit here that would be great, paving the way for sueing Christians for their passive aggressive 'I'll pray for you' nonsense would be amazing. |
![]() |
| Virtually impossible as Anne Wojcicki holds 20% of the outstanding shares and 49% of the voting power of total outstanding shares. That's essentially dictator-level power over the company. I believe the next largest shareholder is Richard Branson. Source: https://investors.23andme.com/news-releases/news-release-det...
Despite the promising drug development news, the CEO signaled last month that she was willing to let public investors get hosed, with a low ball take-private offer of $0.40/share. I believe this pissed both public investors and the board members off. I'm not sure if the positive phase 2 results were icing on the cake. Quite honestly this company is a ripe target for acquisition by a biopharma company like GSK or Roche. |
![]() |
| Unless the data turns out to be fraudulent (ugh!), then 23 & Me seems like it has actually promising products currently going through their development process(es). |
![]() |
| How would that avoid PII? One assumes there would need to be an email address to recover that account, and that would likely link to every single detail about the owner. |
![]() |
| > write long random number on it
Human brains when generating 'random' numbers: https://xkcd.com/221/ > Once a month company publishes one giant zip with all the monthly result where you find your file by that random number you wrote. Given how much of our appearance is due to genetics, that's basically all the harm with none of the convenience. |
![]() |
| Something I just remembered about this company: after a data breach, they tried retroactively changing ToS to shield from lawsuits
Frankly I find this lack of accountability utterly repulsive. Anything this leadership touches is poison to me > Through a mechanism called acceptance by silence or inaction, 23andMe stipulated that customers must explicitly tell the company they disagree with the new terms within 30 days of being notified of the changes or they will be locked into the terms automatically. > After the attack, hackers published around 1 million data points about users with Ashkenazi Jewish heritage and information about more than 300,000 users with Chinese heritage. https://www.axios.com/2023/12/07/23andme-terms-of-service-up... |
![]() |
| As usual: “It depends’. Data on gene variants related to the first steps in drug metabolism can be quite useful both at home and clinically—e.g, your own responses to ethanol, caffeine, and many over-the-counter and prescribed drugs.
St Jude Children’s Research Hospital routinely genotypes/sequences children before drug treatments to optimize initial doses. It makes a huge difference in outcomes for most cancer patients. But chronic age-related diseases that older individuals care about most are too complicated and too strongly affected by environmental factors to be well predicted by low coverage sequencing or genotyping platforms. Even deep sequencing and perfect telomere-to-telomere personal genome assemblies (still about a $10,000 to 20,000 effort) will not be sufficient. You really need the patient’s full history and deep omics data. Michael P Snyder and colleagues at Stanford are getting close to this type of “future preventive health care” with a focus on type 2 diabetes. https://pubmed.ncbi.nlm.nih.gov/?term=michael+mo+stanford&so... Polygenic risk scores based in simple GWAS results and additive genetic models are uninformative (or minimally useful) wrt clinical care for complex diseases—even those that have moderate heritability. There are simple way too many variables, too many undefined gene-by-environmental effects, and too many non-additive effects (epistasis). Polygenic risk scores typically account for less than 20% of variance in disease traits. Coming around full circle though—-these platforms ARE useful for pharmacogenetic predictions of initial metabolic processing of drugs—- getting us closer to the right dose the first time. And the SNP genotypes generated by 23andMe are also valuable predictors for a subset of variants that contribute to nearly monogenic disorders. |
![]() |
| The company was not very well run so I’m not surprised. Their stock price has tanked over 10x since IPO, and it dropped by half in the employee lockout period after IPO. |
![]() |
| Did your relative?
I'm not a geneticist so I could be totally off the mark; but, to my understanding, the painful part is that is a big disclosure right there |
![]() |
| Doesn't matter. If they're talking to you say you need your lawyer present -- that will end the interrogation, and you might never need a lawyer. But if you don't say that you might end up convicted. |
![]() |
| The company seems to be in rough condition. Say they go bankrupt and an ad-tech data broker buys their assets. Now DraftKings can laser focus their ads to folks genetically predisposed to addiction. |
![]() |
| I took an alternate approach: my genome is freely available: https://my.pgp-hms.org/profile/hu80855C
When I was sequenced, a bunch of genetic counselors at Illumina analyzed it and said they couldn't find a single gene mutation that was linked to increased risk of disease, which was a surprise to me but is really absence of information rather than information of absence. |
![]() |
| This is very unethical and you should be ashamed of yourself. You leaked 50% of your direct relatives here, 50% of any future or current children you have. Did you ask them for consent? |
![]() |
| Why? It's just a record of a group of letters, not your soul. I upload my dna records everywhere I can. Sure I had some surprises but in general I benefit from those services. |
![]() |
| Thankfully time only goes forward and since I don't expect a large scale ethnic cleansing among the developed world since our birth rates are already below replacement I think we're fine. |
![]() |
| Book recommendation for you: “IBM And The Holocaust” by Edwin Black.
If IBM (then known as Hollerith) could do that much damage with German census data on punchcards… |
![]() |
| What is a good alternative to 23andMe that retain confidentiality, and is it enough to use/play with Python packages for genetics |
![]() |
| Responds: Airbnb, Stripe, Amazon, Apple, USAA, Microsoft, OpenAI, AngelList, Mercury, Coinbase, YCombinator (up to 2022) and more.
Didn't: 23andme, VLTA, Reddit, YCombinator (post 2022) |
![]() |
| Most of them are minor ideas like the ones I just copy/pasted below. But sometimes they are longer like this one: https://hub.scroll.pub/applecard/applecard.pdf
----- Nope, we don't have one yet though it would be a good idea. I'm looping in Joe for this. Thanks for the nudge! Nathan Co-founder & CTO Help: www.airbnb.com/help Recent press: Washington Post http://bit.ly/KkEzT On Mon, Oct 12, 2009 at 11:12 AM, Breck Yunits just curious why you don't have a favicon (or maybe it just doesn't work on my computer)? - favicon police ---- Date: Mon, 28 Oct 2019 06:19:24 -1000 Subject: Idea: OpenAI should invest in TabNine which uses GPT-2 From: Breck Yunits The product is one in a million. Hard to code without it now. But the kid seems overworked and like he's struggling to keep up with demand (https://github.com/zxqfl/TabNine/issues/179#issuecomment-547...) |
![]() |
| “Nearly every baby born in the U.S. has blood drawn in the immediate hours after their birth, allowing the baby to be tested for a panel of potentially life-threatening inherited disorders. This is a vital public health program, enabling early treatment of newborns with genetic disorders; for them, it can be the difference between a healthy life and an early death.
But recent news suggests that police are seeking access to these newborn blood samples in criminal investigations. Such use of this trove of genetic material — to hunt for evidence that could implicate a child’s relative in a crime — endangers public trust in this vital health program and threatens all Americans’ right to genetic privacy.” All of our new babies had heel stick blood drawn, won’t the government be the eventual competitor of 23 and me (since Americans don’t care too much about privacy). https://www.aclu.org/news/privacy-technology/police-are-usin... |
The board of directors of 23andMe just resigned in protest. The CEO, Anne Wojcicki (who's sister Susan died of lung cancer last month, and was the former CEO of YouTube) had tried to low ball take the company private at only $0.40 a share -- a more than 96% drop from its deSPAC price.
For reference, right now the market cap of 23andMe is $172 million, its closest competitor Ancestry.com was bought out by the Blackstone group for $4.7 billion, and cumulative sales of KeyTruda - an anti-cancer drug in the same family as the one being developed by 23andMe had cumulative sales of $25 billion by 2023.
Feels like the main thing holding this company back is the CEO and lack of corporate governance (due to majority shareholder control resting in the hands of one person)